Kalaris Therapeutics Inc (KLRS) Stock Score, Valuation & Financial Research

Kalaris Therapeutics Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KLRS

Kalaris Therapeutics Inc does not currently have a complete Wall Street Score. The stored market price is USD 2.66. These figures are a research snapshot, not a buy or sell recommendation.

What Kalaris Therapeutics Inc does

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kalaris Therapeutics is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of therapeutic treatments for prevalent retinal diseases. As a clinical-stage entity, the company does not currently generate product revenue and relies on capital raises and financing activities to fund its ongoing research and development operations.

Products and services

  • The company is developing therapeutic candidates for the treatment of exudative and neovascular retinal diseases, operating as a clinical-stage biopharmaceutical firm.

Customer types

Healthcare providers and patients with retinal diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and the manufacturing of clinical trial materials. Specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Regeneron Pharmaceuticals, Inc. — Developer of Eylea, a leading anti-VEGF therapeutic for retinal diseases. Source

Business strengths to evaluate

  • Focus on high-prevalence retinal disease market Source

Business risks and research considerations

  • Clinical-stage development risks and potential for failure Source
  • Requirement for substantial additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KLRS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.66
Market capitalization:
58.06M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -44.26M
Free cash flow:
USD -43.18M
Cash:
USD 43.17M
Total debt:
USD 1.4M
EPS:
USD -2.02

What stands out

  • Free cash flow is USD -43.18M, negative for the stored period.
  • The balance sheet shows USD 43.17M of cash versus USD 1.4M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 41.77M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KLRS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KLRS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KLRS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KLRS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of KLRS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research KLRS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.